Pharmalittle: We’re reading about FDA commish’s parting thoughts, a warning on RSV shots, and more
Departing FDA leader Robert Califf defended the agency’s record and praised its progress on regulating food
Related Articles
Current Issue | NEJM Catalyst Innovations in Care Delivery
Explore the current issue of NEJM Catalyst Innovations in Care Delivery (Vol. 6 No. 1).
Loneliness and Social Isolation Leave a Mark on the Blood
New research sheds light on the biology underlying the connection between loneliness and social isolation and adverse health outcomes.
Jimmy Carter Took on the Awful Guinea Worm When No One Else Would — And Triumphed – KFF Health News
The effort to end Guinea worm disease relies almost entirely on changes in people’s behavior. There is no cure, no vaccination. When the 39th president…
Can an Overactive Thyroid Cause Fatigue?
You’ve probably heard that having an underactive thyroid (hypothyroidism) can make you feel perpetually tired. But what about hyperthyroidism? Can an overactive thyroid lead to…
FDA Accepts Revised Avacincaptad Pegol sNDA for Geographic Atrophy
After accepting the avacincaptad pegol sNDA on January 6, 2025, the FDA has set a target action date for February 26.
Danone’s use of midwives to give branded infant feeding advice in supermarket sparks anger
Campaigners for impartial nutritional advice are dismayed at a service that seems to be adopting marketing tactics dubbed scandalous 50 years ago. Rebecca Coombes reports…
China says flu cases show signs of easing, respiratory infections still rising
China’s Center For Disease Control and Prevention (CDC) said on Thursday that while the rate of influenza virus in the country has shown signs of…
Pharmalittle: We’re reading about pharma layoffs, Moderna gambling on China, and more
The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023
The People Behind America’s Health – MedCity News
With the election behind us, it’s time to lift healthcare above campaign rhetoric and invest in a care economy that breaks the cycle of chronic…
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Durvalumab plus bevacizumab plus TACE has the potential to set a new standard of care. With additional follow-up of the EMERALD-1 study, future analyses, including…
